Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
23
10
2023
accepted:
25
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven adult patients completed task-based blood oxygen dependent functional magnetic resonance imaging (fMRI) approximately 3 days before and 2 days after receiving 25 mg of psilocybin (n = 5) or 50 mg of diphenhydramine (n = 6). Visual alcohol and emotionally valanced (positive, negative, or neutral) stimuli were presented in block design. Across both alcohol and emotional cues, psilocybin increased activity in the medial and lateral prefrontal cortex (PFC) and left caudate, and decreased activity in the insular, motor, temporal, parietal, and occipital cortices, and cerebellum. Unique to negative cues, psilocybin increased supramarginal gyrus activity; unique to positive cues, psilocybin increased right hippocampus activity and decreased left hippocampus activity. Greater PFC and caudate engagement and concomitant insula, motor, and cerebellar disengagement suggests enhanced goal-directed action, improved emotional regulation, and diminished craving. The robust changes in brain activity observed in this pilot study warrant larger neuroimaging studies to elucidate neural mechanisms of PAT.Trial registration: NCT02061293.
Identifiants
pubmed: 38326432
doi: 10.1038/s41598-024-52967-8
pii: 10.1038/s41598-024-52967-8
doi:
Banques de données
ClinicalTrials.gov
['NCT02061293']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3159Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000038
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Sher, K. J., Grekin, E. R. & Williams, N. A. The development of alcohol use disorders. Annu. Rev. Clin. Psychol. 1, 493–523. https://doi.org/10.1146/annurev.clinpsy.1.102803.144107 (2005).
doi: 10.1146/annurev.clinpsy.1.102803.144107
pubmed: 17716097
Kwako, L. E., Momenan, R., Litten, R. Z., Koob, G. F. & Goldman, D. Addictions neuroclinical assessment: A neuroscience-based framework for addictive disorders. Biol. Psychiatry 80(3), 179–189. https://doi.org/10.1016/j.biopsych.2015.10.024 (2016).
doi: 10.1016/j.biopsych.2015.10.024
pubmed: 26772405
Votaw, V. R., Pearson, M. R., Stein, E. & Witkiewitz, K. The addictions neuroclinical assessment negative emotionality domain among treatment-seekers with alcohol use disorder: Construct validity and measurement invariance. Alcohol. Clin. Exp. Res. 44(3), 679–688. https://doi.org/10.1111/acer.14283 (2020).
doi: 10.1111/acer.14283
pubmed: 31957027
pmcid: 7069798
Voon, V. et al. Addictions NeuroImaging Assessment (ANIA): Towards an integrative framework for alcohol use disorder. Neurosci. Biobehav. Rev. 113(March), 492–506. https://doi.org/10.1016/j.neubiorev.2020.04.004 (2020).
doi: 10.1016/j.neubiorev.2020.04.004
pubmed: 32298710
Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8), 760–773. https://doi.org/10.1016/S2215-0366(16)00104-8 (2016).
doi: 10.1016/S2215-0366(16)00104-8
pubmed: 27475769
pmcid: 6135092
Al-Khalil, K., Vakamudi, K., Witkiewitz, K. & Claus, E. D. Neural correlates of alcohol use disorder severity among nontreatment-seeking heavy drinkers: An examination of the incentive salience and negative emotionality domains of the alcohol and addiction research domain criteria. Alcohol. Clin. Exp. Res. 45(6), 1200–1214. https://doi.org/10.1111/acer.14614 (2021).
doi: 10.1111/acer.14614
pubmed: 33864389
Vollstädt-Klein, S. et al. Validating incentive salience with functional magnetic resonance imaging: Association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients. Addict. Biol. 17(4), 807–816. https://doi.org/10.1111/j.1369-1600.2011.00352.x (2012).
doi: 10.1111/j.1369-1600.2011.00352.x
pubmed: 21790907
Wemm, S. E. et al. A day-by-day prospective analysis of stress, craving and risk of next day alcohol intake during alcohol use disorder treatment. Drug Alcohol Dependence. 12(5), 1–23. https://doi.org/10.1016/j.drugalcdep.2019.107569.A (2020).
doi: 10.1016/j.drugalcdep.2019.107569.A
Stohs, M. E., Schneekloth, T. D., Geske, J. R., Biernacka, J. M. & Karpyak, V. M. Alcohol craving predicts relapse after residential addiction treatment. Alcohol Alcohol. 54(2), 167–172. https://doi.org/10.1093/alcalc/agy093 (2019).
doi: 10.1093/alcalc/agy093
pubmed: 30796778
Burnette, E. M. et al. Novel agents for the pharmacological treatment of alcohol use disorder. Drugs 82(3), 251–274. https://doi.org/10.1007/s40265-021-01670-3 (2022).
doi: 10.1007/s40265-021-01670-3
pubmed: 35133639
pmcid: 8888464
Palpacuer, C. et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2), 220–237. https://doi.org/10.1111/add.13974 (2018).
doi: 10.1111/add.13974
pubmed: 28940866
Jonas, D. E. et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 311(18), 1889–1900. https://doi.org/10.1001/jama.2014.3628 (2014).
doi: 10.1001/jama.2014.3628
pubmed: 24825644
Han, B., Jones, C. M., Einstein, E. B., Powell, P. A. & Compton, W. M. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry 78(8), 922–924. https://doi.org/10.1001/jamapsychiatry.2021.1271 (2021).
doi: 10.1001/jamapsychiatry.2021.1271
pubmed: 34132744
pmcid: 8209593
Mason, B. J. & Heyser, C. J. Alcohol use disorder: The role of medication in recovery. Alcohol Res. Curr. Rev. 41(1), 1–17. https://doi.org/10.35946/arcr.v41.1.07 (2021).
doi: 10.35946/arcr.v41.1.07
Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 29(3), 289–299. https://doi.org/10.1177/0269881114565144 (2015).
doi: 10.1177/0269881114565144
pubmed: 25586396
Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry https://doi.org/10.1001/jamapsychiatry.2022.2096 (2022).
doi: 10.1001/jamapsychiatry.2022.2096
pubmed: 36001306
pmcid: 9403854
Kometer, M. et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol. Psychiatry 72(11), 898–906. https://doi.org/10.1016/j.biopsych.2012.04.005 (2012).
doi: 10.1016/j.biopsych.2012.04.005
pubmed: 22578254
von Rotz, R. et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809 (2023).
doi: 10.1016/j.eclinm.2022.101809
Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443 (2022).
doi: 10.1056/NEJMoa2206443
pubmed: 36322843
Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399–408 (2018).
doi: 10.1007/s00213-017-4771-x
pubmed: 29119217
Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. https://doi.org/10.1177/0269881116675513 (2016).
doi: 10.1177/0269881116675513
pubmed: 27909165
pmcid: 5367557
Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. https://doi.org/10.1177/0269881116675512 (2016).
doi: 10.1177/0269881116675512
pubmed: 27909164
pmcid: 5367551
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28(11), 983–992. https://doi.org/10.1177/0269881114548296 (2014).
doi: 10.1177/0269881114548296
pubmed: 25213996
pmcid: 4286320
Ross, S. et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol. Transl. Sci. 4(2), 553–562. https://doi.org/10.1021/acsptsci.1c00020 (2021).
doi: 10.1021/acsptsci.1c00020
pubmed: 33860185
pmcid: 8033770
Goldberg, S. B. et al. Post-acute psychological effects of classical serotonergic psychedelics: A systematic review and meta-analysis. Psychol. Med. https://doi.org/10.1017/S003329172000389X (2020).
doi: 10.1017/S003329172000389X
pubmed: 33143790
pmcid: 7855004
Erritzoe, D. et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr. Scand. 138(5), 368–378. https://doi.org/10.1111/acps.12904 (2018).
doi: 10.1111/acps.12904
pubmed: 29923178
pmcid: 6220878
MacLean, K. A., Johnson, M. W. & Griffiths, R. R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J. Psychopharmacol. 25(11), 1453–1461. https://doi.org/10.1177/0269881111420188 (2011).
doi: 10.1177/0269881111420188
pubmed: 21956378
pmcid: 3537171
Doss, M. K. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl. Psychiatry 11(1), 1–10. https://doi.org/10.1038/s41398-021-01706-y (2021).
doi: 10.1038/s41398-021-01706-y
McKenna, M. et al. T263. Psilocybin improves cognitive control and downregulates parietal cortex in treatment-seeking smokers. Biol. Psychiatry 83(9), S231–S232. https://doi.org/10.1016/j.biopsych.2018.02.600 (2018).
doi: 10.1016/j.biopsych.2018.02.600
Murphy-Beiner, A. & Soar, K. Ayahuasca’s ‘afterglow’: Improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology 237(4), 1161–1169. https://doi.org/10.1007/s00213-019-05445-3 (2020).
doi: 10.1007/s00213-019-05445-3
pubmed: 31927605
Kiraga, M. K. et al. Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being. Front. Pharmacol. 12, 1–14. https://doi.org/10.3389/fphar.2021.721537 (2021).
doi: 10.3389/fphar.2021.721537
Bogenschutz, M. P. et al. Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front. Pharmacol. 9, 1–7. https://doi.org/10.3389/fphar.2018.00100 (2018).
doi: 10.3389/fphar.2018.00100
Bogenschutz, M. P. Effects of psilocybin in treatment-seeking adults with AUD [Conference presentation. vol. College on, https://player.vimeo.com/video/838586679?h=7be41de7a0 .
Pagni, B. A. Effects of psilocybin-assisted treatment on personality traits and their relationship with self-compassion among individuals with alcohol use disorder [Conference presentation]. (Psychedelic Sci., 2023).
Keyser-Marcus, L. A., Ramey, T., Bjork, J., Adams, A. & Moeller, F. G. Development and feasibility study of an addiction-focused phenotyping assessment battery. Am. J. Addict. 30(4), 398–405. https://doi.org/10.1111/ajad.13170 (2021).
doi: 10.1111/ajad.13170
pubmed: 33908104
pmcid: 8243823
Kähönen, J. Psychedelic unselfing: Self-transcendence and change of values in psychedelic experiences. Front. Psychol. 14(June), 1–20. https://doi.org/10.3389/fpsyg.2023.1104627 (2023).
doi: 10.3389/fpsyg.2023.1104627
Smigielski, L., Scheidegger, M., Kometer, M. & Vollenweider, F. X. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage 196, 207–215. https://doi.org/10.1016/j.neuroimage.2019.04.009 (2019).
doi: 10.1016/j.neuroimage.2019.04.009
pubmed: 30965131
Wise, T. et al. Instability of default mode network connectivity in major depression: A two-sample confirmation study. Transl. Psychiatry https://doi.org/10.1038/tp.2017.40 (2017).
doi: 10.1038/tp.2017.40
pubmed: 28440813
pmcid: 5416685
Carhart-Harris, R. L. et al. Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci. Rep. 7(1), 1–11. https://doi.org/10.1038/s41598-017-13282-7 (2017).
doi: 10.1038/s41598-017-13282-7
Mertens, L. J. et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J. Psychopharmacol. 34(2), 167–180. https://doi.org/10.1177/0269881119895520 (2020).
doi: 10.1177/0269881119895520
pubmed: 31941394
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J. & Gri, R. R. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci. Rep. https://doi.org/10.1038/s41598-020-59282-y (2020).
doi: 10.1038/s41598-020-59282-y
pubmed: 33235229
pmcid: 7686305
Perkins, D., Pagni, B. A., Sarris, J., Barbosa, P. C. R. & Chenhall, R. Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Front. Pharmacol. https://doi.org/10.3389/fphar.2022.884703 (2022).
doi: 10.3389/fphar.2022.884703
pubmed: 36386199
pmcid: 9643165
Bogenschutz, M. P. & Forcehimes, A. A. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J. Humanist. Psychol. 57(4), 389–414. https://doi.org/10.1177/0022167816673493 (2017).
doi: 10.1177/0022167816673493
First, M. B. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), American. Clin. Version (Administration Booklet) (Psychiatr. Publ. Inc., 1997).
Sobell, L. C. & Sobell, M. B. Timeline followback: user’s guide. Addiction Research Foundation= Fondation de la recherche sur la toxicomanie (1996).
Flannery, B. A., Volpicelli, J. R. & Pettinati, H. M. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol. Clin. Exp. Res. 23(8), 1289–1295. https://doi.org/10.1111/j.1530-0277.1999.tb04349.x (1999).
doi: 10.1111/j.1530-0277.1999.tb04349.x
pubmed: 10470970
Vollstädt-Klein, S. et al. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 105(10), 1741–1749. https://doi.org/10.1111/j.1360-0443.2010.03022.x (2010).
doi: 10.1111/j.1360-0443.2010.03022.x
pubmed: 20670348
Lang, P. J., Bradley, M. M. & Cuthbert, B. N. International affective picture system (IAPS): Technical manual and affective ratings. NIMH Cent. Study Emot. Atten. 1(39–58), 3 (1997).
Nieto-Castanon, A. FMRI denoising pipeline. Handb. Funct. Connect. Magn. Reson. Imaging methods CONN, 17–25 (2020).
J. S. Siegel et al. Psilocybin desynchronizes brain networks. (2023).
Cr, L. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 159, 70–78. https://doi.org/10.1016/j.neuroimage.2017.07.020 (2017).
doi: 10.1016/j.neuroimage.2017.07.020
Zeng, J. et al. Neurobiological correlates of cue-reactivity in alcohol-use disorders: A voxel-wise meta-analysis of fMRI studies. Neurosci. Biobehav. Rev. 128, 294–310. https://doi.org/10.1016/j.neubiorev.2021.06.031 (2021).
doi: 10.1016/j.neubiorev.2021.06.031
pubmed: 34171325
Schacht, J. P., Anton, R. F. & Myrick, H. Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-analysis and systematic review. Addict. Biol. 18(1), 121–133. https://doi.org/10.1111/j.1369-1600.2012.00464.x (2013).
doi: 10.1111/j.1369-1600.2012.00464.x
pubmed: 22574861
Chester, D. S., Lynam, D. R., Milich, R. & DeWall, C. N. Craving versus control: Negative urgency and neural correlates of alcohol cue reactivity. Drug Alcohol Depend. 163, S25–S28. https://doi.org/10.1016/j.drugalcdep.2015.10.036 (2016).
doi: 10.1016/j.drugalcdep.2015.10.036
pubmed: 27306727
pmcid: 7408295
Mollick, J. A. & Kober, H. Computational models of drug use and addiction: A review. J. Abnorm. Psychol. 129(6), 544–555. https://doi.org/10.1037/abn0000503 (2020).
doi: 10.1037/abn0000503
pubmed: 32757599
pmcid: 7416739
Kinley, I., Amlung, M. & Becker, S. Pathologies of precision: A Bayesian account of goals, habits, and episodic foresight in addiction. Brain Cogn. https://doi.org/10.1016/j.bandc.2022.105843 (2022).
doi: 10.1016/j.bandc.2022.105843
pubmed: 35066361
Pink-Hashkes, S., van Rooij, I. & Kwisthout, J. Perception is in the details: A predictive coding account of the psychedelic phenomenon. In CogSci 2017-Proc. 39th Annu. Meet. Cogn. Sci. Soc. Comput. Found. Cogn., 2907–2912 (2017).
Blaine, S. K. et al. Association of prefrontal-striatal functional pathology with alcohol abstinence days at treatment initiation and heavy drinking after treatment initiation. Am. J. Psychiatry 177(11), 1048–1059. https://doi.org/10.1176/appi.ajp.2020.19070703 (2020).
doi: 10.1176/appi.ajp.2020.19070703
pubmed: 32854534
pmcid: 7606814
Seo, D. et al. Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk. JAMA Psychiatry 70(7), 727–739. https://doi.org/10.1001/jamapsychiatry.2013.762 (2013).
doi: 10.1001/jamapsychiatry.2013.762
pubmed: 23636842
pmcid: 3788824
Northoff, G. et al. Self-referential processing in our brain—a meta-analysis of imaging studies on the self. Neuroimage 31(1), 440–457. https://doi.org/10.1016/j.neuroimage.2005.12.002 (2006).
doi: 10.1016/j.neuroimage.2005.12.002
pubmed: 16466680
Volkow, N. D. et al. In Cocaine Abusers, vol. 49, no. 3, 1–18 https://doi.org/10.1016/j.neuroimage.2009.10.088.Cognitive (2011).
Kim, S. M., Han, D. H., Min, K. J., Kim, B. N. & Cheong, J. H. Brain activation in response to craving- and aversion-inducing cues related to alcohol in patients with alcohol dependence. Drug Alcohol Depend. 141, 124–131. https://doi.org/10.1016/j.drugalcdep.2014.05.017 (2014).
doi: 10.1016/j.drugalcdep.2014.05.017
pubmed: 24939441
Suzuki, S. et al. Regulation of craving and negative emotion in alcohol use disorder. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 5(2), 239–250. https://doi.org/10.1016/j.bpsc.2019.10.005 (2020).
doi: 10.1016/j.bpsc.2019.10.005
pubmed: 31892465
Kober, H. et al. Prefrontal-striatal pathway underlies cognitive regulation of craving. Proc. Natl. Acad. Sci. USA 107(33), 14811–14816. https://doi.org/10.1073/pnas.1007779107 (2010).
doi: 10.1073/pnas.1007779107
pubmed: 20679212
pmcid: 2930456
Hester, R. & Garavan, H. Neural mechanisms underlying drug-related cue distraction in active cocaine users. Pharmacol. Biochem. Behav. 93(3), 270–277. https://doi.org/10.1016/j.pbb.2008.12.009 (2009).
doi: 10.1016/j.pbb.2008.12.009
pubmed: 19135471
Ames, S. L. et al. Neural correlates of a Go/NoGo task with alcohol stimuli in light and heavy young drinkers. Behav. Brain Res. 274, 382–389. https://doi.org/10.1016/j.bbr.2014.08.039 (2014).
doi: 10.1016/j.bbr.2014.08.039
pubmed: 25172182
Beylergil, S. B. et al. Dorsolateral prefrontal cortex contributes to the impaired behavioral adaptation in alcohol dependence. NeuroImage Clin. 15, 80–94. https://doi.org/10.1016/j.nicl.2017.04.010 (2017).
doi: 10.1016/j.nicl.2017.04.010
pubmed: 28491495
pmcid: 5413198
Boggio, P. S. et al. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study. Drug Alcohol Depend. 92(1–3), 55–60. https://doi.org/10.1016/j.drugalcdep.2007.06.011 (2008).
doi: 10.1016/j.drugalcdep.2007.06.011
pubmed: 17640830
Gattuso, J. J. et al. Default mode network modulation by psychedelics: A systematic review. Int. J. Neuropsychopharmacol. 26(3), 155–188. https://doi.org/10.1093/ijnp/pyac074 (2023).
doi: 10.1093/ijnp/pyac074
pubmed: 36272145
Balleine, B. W. & O’Doherty, J. P. Human and rodent homologies in action control: Corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 35(1), 48–69. https://doi.org/10.1038/npp.2009.131 (2010).
doi: 10.1038/npp.2009.131
pubmed: 19776734
Courtney, K. E., Ghahremani, D. G. & Ray, L. A. Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addict. Biol. 18(3), 593–604. https://doi.org/10.1111/adb.12013 (2013).
doi: 10.1111/adb.12013
pubmed: 23240858
Strosche, A. et al. Investigation of brain functional connectivity to assess cognitive control over cue-processing in alcohol use disorder. Addict. Biol. 26(1), 1–13. https://doi.org/10.1111/adb.12863 (2021).
doi: 10.1111/adb.12863
Vollstädt-Klein, S. et al. Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: A randomized trial. Biol. Psychiatry 69(11), 1060–1066. https://doi.org/10.1016/j.biopsych.2010.12.016 (2011).
doi: 10.1016/j.biopsych.2010.12.016
pubmed: 21292243
Moulton, E. A., Elman, I., Becerra, L. R., Goldstein, R. Z. & Borsook, D. The cerebellum and addiction: Insights gained from neuroimaging research. Addict. Biol. 19(3), 317–331. https://doi.org/10.1111/adb.12101 (2014).
doi: 10.1111/adb.12101
pubmed: 24851284
pmcid: 4031616
Habas, C. Functional connectivity of the cognitive cerebellum. Front. Syst. Neurosci. 15, 1–8. https://doi.org/10.3389/fnsys.2021.642225 (2021).
doi: 10.3389/fnsys.2021.642225
Ju, A., Fernandez-Arroyo, B., Wu, Y., Jacky, D. & Beyeler, A. Expression of serotonin 1A and 2A receptors in molecular- and projection- defined neurons of the mouse insular cortex. Mol. Brain. 13(1), 1-13. https://doi.org/10.1186/s13041-020-00605-5 (2020).
doi: 10.1186/s13041-020-00605-5
Naqvi, N. H., Gaznick, N., Tranel, D. & Bechara, A. The insula: A critical neural substrate for craving and drug seeking under conflict and risk. Ann. N. Y. Acad. Sci. 1316(1), 53–70. https://doi.org/10.1111/nyas.12415 (2014).
doi: 10.1111/nyas.12415
pubmed: 24690001
pmcid: 4114146
Beraha, E. et al. Hemispheric asymmetry for affective stimulus processing in healthy subjects—A fMRI study. PLoS ONE 7(10), 1–9. https://doi.org/10.1371/journal.pone.0046931 (2012).
doi: 10.1371/journal.pone.0046931
Agin-Liebes, G. et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol. Addict. Behav. https://doi.org/10.1037/adb0000935 (2023).
doi: 10.1037/adb0000935
pubmed: 37276086
Koban, L., Wager, T. D. & Kober, H. A neuromarker for drug and food craving distinguishes drug users from non-users. Nat. Neurosci. https://doi.org/10.1038/s41593-022-01228-w (2022).
doi: 10.1038/s41593-022-01228-w
pubmed: 36536243
pmcid: 9435464
Kragel, P. A., Reddan, M. C., LaBar, K. S. & Wager, T. D. Emotion schemas are embedded in the human visual system. Sci. Adv. https://doi.org/10.1126/sciadv.aaw4358 (2019).
doi: 10.1126/sciadv.aaw4358
pubmed: 31355334
pmcid: 6656543
Magalhaes, A. A., Oliveira, L., Pereira, M. G. & Menezes, C. B. Does meditation alter brain responses to negative stimuli? A systematic review. Front. Hum. Neurosci. https://doi.org/10.3389/fnhum.2018.00448 (2018).
doi: 10.3389/fnhum.2018.00448
pubmed: 30483083
pmcid: 6243128
Fujino, M., Ueda, Y., Mizuhara, H., Saiki, J. & Nomura, M. Open monitoring meditation reduces the involvement of brain regions related to memory function. Sci. Rep. 8(1), 1–10. https://doi.org/10.1038/s41598-018-28274-4 (2018).
doi: 10.1038/s41598-018-28274-4